Cantor Fitzgerald reiterates Overweight rating on ORIC Pharmaceuticals stock

ORIC Pharmaceuticals (NASDAQ:ORIC) received a reiterated Overweight rating from Cantor Fitzgerald, which deems the biopharmaceutical company significantly undervalued despite strong financials and multiple upcoming catalysts, including updates for its lead prostate cancer asset ORIC-944. The firm notes that the current stock price implies a low probability of success for ORIC-944, a mechanism validated by competitor data, while other analysts also maintain Buy ratings and higher price targets as the company prepares for potential Phase 3 trials for ORIC-944 and ORIC-114 in 2026.

Analysis

ORIC Pharmaceuticals (ORIC) is garnering significant bullish sentiment from Wall Street, anchored by a consensus view that the company is substantially undervalued relative to its pipeline potential. Cantor Fitzgerald reiterated an Overweight rating, asserting the current share price of $10.41 implies a less than 15% probability of success for its lead prostate cancer asset, ORIC-944. This valuation appears conservative, particularly as the drug's mechanism, a PRC2 inhibitor, has been partially de-risked by compelling data from a competitor's asset, Pfizer's mevrometostat, which demonstrated a progression-free survival hazard ratio of 0.5 in a controlled trial. The positive outlook is reinforced by other analysts, with Guggenheim and Ladenburg Thalmann initiating with Buy ratings and price targets of $18.00 and $15.00, respectively, while Jefferies raised its target to $23.00. Operationally, the company is preparing for pivotal trials in 2026 for its key assets, ORIC-944 and ORIC-114, a move underscored by the strategic appointment of a Chief Technical Officer. Financially, ORIC is well-positioned with more cash than debt and a robust current ratio of 16.13, providing a solid foundation to navigate a catalyst-rich 12-month period that includes multiple data readouts.

Key Decisions for Investors

• Given the strong analyst consensus and a valuation that appears to heavily discount the lead asset's potential, investors may view the current price as an attractive entry point ahead of key clinical and corporate milestones.
• Portfolio managers should monitor the upcoming Phase 3 readout for Pfizer's mevrometostat, as positive data would further validate ORIC-944's mechanism and could serve as a significant de-risking event.
• While clinical trial risk remains inherent to the biotech sector, ORIC's strong balance sheet, with more cash than debt, mitigates near-term financing concerns and provides a runway to achieve its upcoming data readouts for ORIC-944 and ORIC-114.
• Consider the multiple price targets from analysts ($15, $18, $23), which are substantially higher than the current price, as a gauge of potential upside if the upcoming catalysts prove favorable.